Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,048.42 -23.21 (-0.46%) Dow
38,085.80 -375.12 (-0.98%) Nasdaq
15,611.76 -100.99 (-0.64%) Bitcoin USD
64,825.80 +819.12 (+1.28%) CMC Crypto 200
1,397.55 +14.98 (+1.08%)
Sanofi (SAN.PA)
| Previous close | 87.70 |
| Open | 87.68 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 87.63 - 92.56 |
| 52-week range | 80.60 - 104.90 |
| Volume | |
| Avg. volume | 1,365,420 |
| Market cap | 115.862B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | 21.31 |
| EPS (TTM) | 4.30 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 3.76 (4.29%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | 105.70 |
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
ZacksSanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.
- Reuters
UPDATE 2-Sanofi profit slips on generic competition and currency effects
Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.
